Difference between revisions of "Durvalumab (Imfinzi)"
m |
|||
| Line 18: | Line 18: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
===[[Non-small cell lung cancer]]=== | ===[[Non-small cell lung cancer]]=== | ||
| − | *2/16/2018: FDA approved for patients with unresectable stage III [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] whose disease has not progressed following [[Regimen_classes#Platinum-based_chemoradiation|concurrent platinum-based chemotherapy and radiation therapy]]. ''(New disease entity)'' | + | *2/16/2018: FDA approved for patients with unresectable stage III [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] whose disease has not progressed following [[Regimen_classes#Platinum-based_chemoradiation|concurrent platinum-based chemotherapy and radiation therapy]]. ''(New disease entity; based on PACIFIC)'' |
===[[Small cell lung cancer]]=== | ===[[Small cell lung cancer]]=== | ||
| − | *3/27/2020: Approved in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage [[small cell lung cancer]] (ES-SCLC). ''(New disease entity)'' | + | *3/27/2020: Approved in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage [[small cell lung cancer]] (ES-SCLC). ''(New disease entity; based on CASPIAN)'' |
==Withdrawn indications== | ==Withdrawn indications== | ||
Revision as of 01:13, 26 May 2021
General information
Class/mechanism: PD-L1 blocking antibody. PD-L1 (programmed death-1 ligand 1) expressed on tumor cells and tumor-infiltrating immune cells can result in inhibition of anti-tumor immune responses. Durvalumab binds to PD-1 and CD80 (B7.1) receptors on T-cells and antigen presenting cells and prevents PD-L1's inhibitory effects on the immune system. As a result, durvalumab stimulates immune responses, including anti-tumor immune effects. [1][2][3][4]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Diseases for which it was used
Patient drug information
History of changes in FDA indication
Non-small cell lung cancer
- 2/16/2018: FDA approved for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. (New disease entity; based on PACIFIC)
Small cell lung cancer
- 3/27/2020: Approved in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). (New disease entity; based on CASPIAN)
Withdrawn indications
Bladder cancer
- 5/1/2017: Granted FDA accelerated approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy (Initial approval)
- 5/1/2017: Granted FDA accelerated approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (Initial approval)
- 2/22/2021: Indication withdrawn by manufacturer after the confirmatory trial (DANUBE) did not meet its primary endpoints.
Also known as
- Code name: MEDI4736
- Brand name: Imfinzi